JP2019509014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509014A5 JP2019509014A5 JP2018526708A JP2018526708A JP2019509014A5 JP 2019509014 A5 JP2019509014 A5 JP 2019509014A5 JP 2018526708 A JP2018526708 A JP 2018526708A JP 2018526708 A JP2018526708 A JP 2018526708A JP 2019509014 A5 JP2019509014 A5 JP 2019509014A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- polypeptide
- binding
- human
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 21
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 8
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 108091006112 ATPases Proteins 0.000 claims 5
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 230000001965 increasing effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108010080422 CD39 antigen Proteins 0.000 claims 2
- 239000004214 Fast Green FCF Substances 0.000 claims 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000003828 downregulation Effects 0.000 claims 2
- 230000002255 enzymatic effect Effects 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- GSEKYIWUAPZIEF-UHFFFAOYSA-N ismine hydrochloride Natural products CNC1=CC=CC=C1C(C(=C1)CO)=CC2=C1OCO2 GSEKYIWUAPZIEF-UHFFFAOYSA-N 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 238000006386 neutralization reaction Methods 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 101150046224 ABAT gene Proteins 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 101100501552 Homo sapiens ENTPD1 gene Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 102000053350 human FCGR3B Human genes 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- WWJZWCUNLNYYAU-UHFFFAOYSA-N temephos Chemical group C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258701P | 2015-11-23 | 2015-11-23 | |
| US62/258,701 | 2015-11-23 | ||
| US201562263760P | 2015-12-07 | 2015-12-07 | |
| US62/263,760 | 2015-12-07 | ||
| US201562267343P | 2015-12-15 | 2015-12-15 | |
| US62/267,343 | 2015-12-15 | ||
| US201662320738P | 2016-04-11 | 2016-04-11 | |
| US62/320,738 | 2016-04-11 | ||
| US201662404779P | 2016-10-06 | 2016-10-06 | |
| US62/404,779 | 2016-10-06 | ||
| PCT/EP2016/078395 WO2017089334A1 (en) | 2015-11-23 | 2016-11-22 | Cd39 vascular isoform targeting agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019509014A JP2019509014A (ja) | 2019-04-04 |
| JP2019509014A5 true JP2019509014A5 (enExample) | 2019-12-12 |
Family
ID=57391960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526708A Pending JP2019509014A (ja) | 2015-11-23 | 2016-11-22 | Ｃｄ３９血管アイソフォームターゲティング剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190153113A1 (enExample) |
| EP (1) | EP3380519A1 (enExample) |
| JP (1) | JP2019509014A (enExample) |
| AU (1) | AU2016359790A1 (enExample) |
| CA (1) | CA3005986A1 (enExample) |
| WO (1) | WO2017089334A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2618292T3 (es) | 2008-01-31 | 2017-06-21 | Inserm - Institut National De La Sante Et De La Recherche Medicale | Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| IL269150B2 (en) | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
| WO2018209324A2 (en) | 2017-05-11 | 2018-11-15 | The Broad Institute, Inc. | Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| US11345757B2 (en) * | 2017-07-31 | 2022-05-31 | Trishula Therapeutics, Inc. | Anti-CD39 antibodies |
| JP7274469B2 (ja) * | 2017-10-06 | 2023-05-16 | イナート・ファルマ・ソシエテ・アノニム | Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 |
| AU2018368541B2 (en) * | 2017-11-15 | 2025-06-12 | Innate Pharma | Potentiating the effect of ATP release |
| WO2019138005A2 (en) * | 2018-01-10 | 2019-07-18 | Bioinvent International Ab | Novel combination and use of antibodies |
| CA3097916A1 (en) | 2018-05-03 | 2019-11-07 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom |
| TWI869346B (zh) * | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2019241707A1 (en) * | 2018-06-14 | 2019-12-19 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition antibody-mediated target cytosis |
| US11377503B2 (en) | 2018-06-18 | 2022-07-05 | Innate Pharma | Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide |
| SG11202106963YA (en) | 2019-01-11 | 2021-07-29 | Omeros Corp | Methods and compositions for treating cancer |
| US12453738B2 (en) | 2019-03-12 | 2025-10-28 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| US12098212B2 (en) | 2019-08-12 | 2024-09-24 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells |
| CN112714768B (zh) * | 2019-08-27 | 2025-02-18 | 科望(苏州)生物医药科技有限公司 | 新型抗cd39抗体 |
| MX2022003005A (es) | 2019-09-16 | 2022-04-07 | Surface Oncology Inc | Composiciones y metodos de anticuerpos anti-cd39. |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| CN114651013B (zh) * | 2019-11-05 | 2025-03-14 | 北京加科思新药研发有限公司 | 对cd39具有特异性的结合分子及其用途 |
| US20230036592A1 (en) * | 2021-06-03 | 2023-02-02 | Surface Oncology, Inc. | Methods of treating cancer with an anti-cd39 antibody and pembrolizumab |
| WO2023165561A1 (en) * | 2022-03-03 | 2023-09-07 | Arcus Biosciences, Inc. | Anti-cd39 antibodies and use thereof |
| KR20250006965A (ko) | 2022-04-29 | 2025-01-13 | 퓨리노미아 바이오테크, 아이엔씨. | 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물 |
| WO2024115935A1 (en) * | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2618292T3 (es) * | 2008-01-31 | 2017-06-21 | Inserm - Institut National De La Sante Et De La Recherche Medicale | Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras |
| EP2654789B1 (en) * | 2010-12-22 | 2018-05-30 | Orega Biotech | Antibodies against human cd39 and use thereof |
| JP6141834B2 (ja) * | 2011-06-06 | 2017-06-07 | ノヴォ ノルディスク アー／エス | 治療抗体 |
-
2016
- 2016-11-22 EP EP16800926.4A patent/EP3380519A1/en not_active Withdrawn
- 2016-11-22 CA CA3005986A patent/CA3005986A1/en active Pending
- 2016-11-22 WO PCT/EP2016/078395 patent/WO2017089334A1/en not_active Ceased
- 2016-11-22 US US15/778,202 patent/US20190153113A1/en not_active Abandoned
- 2016-11-22 AU AU2016359790A patent/AU2016359790A1/en not_active Abandoned
- 2016-11-22 JP JP2018526708A patent/JP2019509014A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509014A5 (enExample) | ||
| ES3038421T3 (en) | Humanized or chimeric cd3 antibodies | |
| CN109715663B (zh) | 结合生长抑素受体2的异源二聚抗体 | |
| JP6718305B2 (ja) | 細胞傷害誘導治療剤 | |
| US12227569B2 (en) | Humanized antibodies with increased stability | |
| CN101952454B (zh) | 具有减弱的Fc配体亲和性的抗IFNAR1抗体 | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2013545455A5 (enExample) | ||
| CA3046082A1 (en) | Antibodies and methods of use thereof | |
| JP2014520788A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| TW202016142A (zh) | 用於治療癌症之組合物及方法 | |
| US11299551B2 (en) | Composite binding molecules targeting immunosuppressive B cells | |
| RU2019123112A (ru) | Анти-il-5 антитела | |
| WO2021173844A1 (en) | C19 c38 bispecific antibodies | |
| CN110709417A (zh) | 具有突变人IgG4的多肽 | |
| RU2015129655A (ru) | Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела | |
| EP4417626A1 (en) | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof | |
| JP2023076596A5 (enExample) | ||
| JP2023511652A (ja) | 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用 | |
| US20240352156A1 (en) | Antibodies targeting immunosuppressive b cells | |
| CN118139639A (zh) | 治疗与免疫抑制b细胞相关联的癌症的方法 | |
| KR20210116429A (ko) | 이중특이적 항-cd37 항체를 포함하는 제약 조성물 | |
| AU2017365367A1 (en) | Monoclonal antibody directed to FGFR1 | |
| WO2018095932A1 (en) | Monoclonal antibody directed to fgfr1 |